國泰集團(603977.SH):國鯤微電芯片模組生產量可覆蓋公司電子雷管需求外,也為其他電子雷管生產企業提供芯片模組
格隆匯1月4日丨國泰集團(603977.SH)近期投資者關係活動記錄表顯示,公司控股子公司國鯤微電主營電子數碼雷管芯片模組的製造及銷售,屬於集成電路產業,一期2000萬發電子雷管芯片模組已達產達標,二期實現年產5000萬發電子雷管芯片模組的擴能工作前期準備階段。國鯤微電率先在行業採用先進的全自動化生產設備,未來3年爭取獲得“國家高新”“專精特新”等企業認證。目前公司電子雷管許可產能為2510萬發,國鯤微電芯片模組生產量可覆蓋公司電子雷管需求外,也為其他電子雷管生產企業提供芯片模組。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.